Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maillart Elisabeth, Rollot Fabien, Leray Emmanuelle, Benyahya Lakhdar, Bourre Bertrand, Carra-Dallière Clarisse, Casey Romain, Deiva Kumaran, Girod Catherine, Guennoc Anne-Marie, Marignier Romain, Labauge Pierre, Bensa Caroline, De Sèze Jérôme, Berger Eric, Biotti Damien, Bresch Saskia, Thouvenot Eric, Moreau Thibault, Derache Nathalie, Zéphir Hélène, Le Page Emmanuelle, Clavelou Pierre, Casez Olivier, Laplaud David, Kwiatkowski Arnaud, Grosset-Janin Clara, Pittion-Vouyovitch Sophie, Ruet Aurélie, Dos Santos Amélie, Robert-Varvat Florence, Morel Nathalie, Lebrun-Frenay Christine, Vukusic Sandra
Аннотация
METHODS: We compared pregnancy and birth outcomes in MS women included in RESPONSE, a French prospective cohort, with a recent survey (Enquête Nationale Périnatale (ENP)) describing leading indicators in perinatal epidemiology in France.
RESULTS: On 7 April 2023, 476 pregnancies (461 MS women, 482 expected newborns) from RESPONSE were available. The ENP study reported 12,723 women and 12,939 expected newborns in March 2021. MS patients were older (mean age 32.6 ± 4.4 vs. 30.9 ± 5.3 years, p < 0.001), with similar rate of cesarean (23.8% vs. 21.4%, p = 0.115) and use of locoregional analgesia (86.6% vs. 85.1%, p = 0.51). Preterm birth was less frequent (4.0% vs. 7.0%, p = 0.001). Birthweight of children from MS mothers was similar to general population (3240 ± 477.2 vs. 3264.5 ± 552.9 g, p = 0.22), with slightly more children with SGA (13.4% vs. 9.8%, p = 0.04).
CONCLUSION: This prospective and contemporary comparison of pregnancy in MS women and the French population provides reassuring results. In the future, we need to assess the impact of disease-modifying treatment exposure during conception.